What Flosonics Medical does

Flosonics Medical is a Canadian medical device company founded in 2015 and headquartered in Sudbury, Ontario, that develops the FloPatch FP120 — a wireless, wearable Doppler ultrasound system designed for continuous hemodynamic monitoring in critical care, sepsis, and perioperative fluid management. The device is a single-use adhesive-applied transducer that transmits Doppler waveform data to a clinician-facing display, enabling assessment of fluid responsiveness at the bedside without requiring a cart-based ultrasound operator. The company received FDA 510(k) clearance (K200337) in March 2020 and has built a clinical evidence base of more than 45 peer-reviewed publications supporting the use of the device in sepsis care and fluid management.

The company operates a B2B medical device sales model targeting U.S. enterprise health systems, with named customers including Sutter Health (six or more campuses), Mount Sinai Hospital (first East Coast deployment), El Camino Health, Riverside University Health System, and a large public hospital in Greater Los Angeles. Distribution is enabled through a Vizient Innovative Technology contract (since March 2026) for U.S. health system access and a Lovell Government Services partnership (since November 2024) for federal channels including Veterans Affairs and Department of Defense facilities. Capital structure includes a $5M seed round, a $20M Series C led by New Leaf Venture Partners in March 2024, $7.5M CAD venture debt from RBCx in March 2025, and a strategic investment from Denka Co., Ltd. in July 2026 indicating international expansion intent. The company is led by CEO Eran Lev, with Dr. Jon-Emile Kenny serving as Chief Medical Officer, and has received industry recognition including the 2024 Best in Class Digital Health Award and the Paul and Debra Walker Award in June 2026.

Name

Flosonics Medical

Legal name

Flosonics Medical

Website

https://flosonicsmedical.com

Company type

Private

Founded year

2015

Operating status

Operating

Short description

Flosonics Medical is a Canadian medical device company that develops the FloPatch FP120, a wireless, wearable Doppler ultrasound system for bedside hemodynamic monitoring in sepsis and critical care, sold to U.S. enterprise health systems through direct sales and GPO channels.

Ownership category

akta.pro rank

NAICS

Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

akta.pro secondary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

Keywords

• Wearable medical devices
• Hemodynamic monitoring
• Fluid responsiveness assessment
• Sepsis care technology
• Point-of-care ultrasound

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. FloPatch Device Sales: Sale of the FloPatch wearable Doppler ultrasound device to healthcare systems, hospitals, and clinical facilities. Device is FDA cleared and available by prescription for trained healthcare providers.
2. Consumables/Disposables: Potential recurring revenue from consumables associated with the wearable device platform. Device is a wireless patch that would require periodic replacement.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Flosonics Medical develops and sells FloPatch, a wireless, wearable Doppler ultrasound device that enables bedside, non-invasive hemodynamic monitoring and fluid responsiveness assessment in critically ill patients. The device is FDA 510(k) cleared and is sold to hospitals and integrated health systems for use in emergency departments, ICUs, and sepsis care pathways. Revenue is generated from device sales, multi-year enterprise contracts, and associated consumables.

Product overview

Flosonics Medical offers a single unified product—FloPatch FP120—a wireless, wearable Doppler ultrasound device designed for hemodynamic assessment and fluid responsiveness testing in critical care settings. FloPatch is the company's sole offering, providing real-time carotid artery blood flow measurement using Continuous Wave Doppler technology to help clinicians determine whether patients will respond to IV fluid administration. The device enables point-of-care assessment without requiring specialized ultrasound training, making it accessible to nurses and frontline providers at the bedside.

Differentiator

Problem solved

Functional benefit

Brands

• FloPatch: FDA-cleared wireless, wearable Doppler ultrasound device for real-time hemodynamic assessment and fluid responsiveness evaluation in critical care settings.

Quantifiable outcome

• Total cost savings of $14,498 per patient treated ($1,449,900 for 6-month study duration) when sepsis resuscitation guided by fluid responsiveness
• +5 more outcomes

Named customers5 records

Segments2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered strategic.

• VizientstrategicChannel Partner/ Reseller/ DistributorNation's largest provider-driven healthcare performance improvement company. Awarded Innovative Technology contract for FloPatch following review by hospital experts on Vizient client-led councils. Represents diverse client base including academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks with contract portfolio representing over $156 billion in annual purchasing volume.
• Lovell Government ServicesstrategicChannel Partner/ Reseller/ DistributorGovernment services company partnering to increase access to FloPatch for federal healthcare systems including Veterans Health Administration (VHA), Military Health System (MHS), and Indian Health Service (IHS). Partnership announced in November 2024.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• GE HealthCare: Major incumbent in patient monitoring and ultrasound (POCUS) with Vscan handheld ultrasound and CARESCAPE monitors. Overlaps with Flosonics in hemodynamic assessment workflows and competes for the same hospital capital budgets, though GE's offerings are not wearable.
• Philips: Global incumbent in patient monitoring (IntelliVue) and ultrasound (Lumify handheld POCUS). Broad portfolio overlap with Flosonics' clinical use case, though Philips focuses on cart-based and handheld systems rather than continuous wearable monitoring.
• Mindray: Chinese medical device major with broad patient monitoring and POCUS ultrasound portfolios. Comparable in hemodynamic monitoring use cases, particularly in cost-sensitive hospital segments where Flosonics may face competitive pressure.
• Sonosite (FUJIFILM): POCUS ultrasound systems used in emergency medicine and critical care for hemodynamic assessment, now part of FUJIFILM. Overlaps with Flosonics in bedside fluid responsiveness evaluation, though as a cart-based platform rather than continuous wearable.

Direct peers

• Masimo (LiDCO): Masimo acquired LiDCO, a hemodynamic monitoring company with non-invasive cardiac output technology for fluid management in critical care. Comparable in clinical use case (fluid responsiveness) and patient population, though delivery mechanism differs.
• Edwards Lifesciences: Global leader in hemodynamic monitoring with FloTrac/Vigileo and ClearSight systems used in ICU and perioperative fluid management. Most direct competitor to Flosonics in the hemodynamic monitoring category, though Edwards' products are cart-based and require specialized training rather than wearable.
• ICU Medical: Provides hemodynamic monitoring solutions (acquired from Hospira/Pfizer) including the TruWave disposable pressure transducers and related critical care monitoring products. Direct competitor in hospital fluid management and hemodynamic monitoring workflows.
• Baxter International (Cheetah Medical): Acquired Cheetah Medical in 2022, adding Starling SV non-invasive bioreactance hemodynamic monitoring to Baxter's patient monitoring portfolio. Direct competitor in fluid responsiveness assessment for sepsis and critical care, with substantially larger sales infrastructure.

Emerging players

• Butterfly Network: Handheld single-probe POCUS platform targeting broad clinical use including hemodynamic assessment. Emerging player with similar mission of democratizing ultrasound at the bedside, though Butterfly is a general-purpose ultrasound rather than a specialized hemodynamic monitor.
• Deltex Medical: UK-based developer of esophageal Doppler monitoring (CardioQ) for fluid management in surgical and critical care settings. Comparable in hemodynamic monitoring niche, though Deltex's technology is invasive (esophageal probe) versus Flosonics' non-invasive wearable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/flosonics
• LinkedInlinkedin.com/company/flosonics-medical
• Instagraminstagram.com/flopatch_

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flosonics Medical